PREP-AF试验:高危患者预防术后房颤的可行性随机对照研究方案
PREP-AF是一项双盲随机对照可行性试验,针对经POAF预测模型识别为高危的胸外科大手术患者,术后即刻1:1随机接受短期胺碘酮或安慰剂。主要结局为可行性,包括合格患者识别、同意和随机化数量、干预依从性及未来结局测量。该研究将为后续多中心试验评估预防性胺碘酮能否安全有效降低POAF发生率提供依据。
要点
- 高危胸外科手术患者术后短期胺碘酮预防POAF的可行性随机对照试验。
- 主要结局为可行性指标:合格患者数、同意随机化数、干预依从性及未来结局测量。
- 结果为后续多中心试验评估预防性胺碘酮安全性和有效性提供依据。
核心结论
- 本研究旨在确定在高危胸外科手术患者中开展预防性胺碘酮随机对照试验的可行性。
- 可行性结果将指导后续多中心试验,以明确预防性胺碘酮能否安全有效减少POAF。
研究设计与样本
- PREP-AF为双盲随机对照可行性试验,对象为接受胸外科大手术且经POAF预测模型判定为高危的患者。
- 患者术后即刻按1:1随机接受短期胺碘酮或安慰剂。
- 主要结局为可行性,包括合格患者识别、同意和随机化数量、干预依从性及未来结局测量。
临床怎么用
- 目前尚不能将本方案结果直接用于临床决策,需等待可行性及后续多中心试验结果。
局限性
- 本研究为可行性试验,主要结局非临床有效性,样本量和设计不足以评估胺碘酮对POAF发生率的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative atrial fibrillation (POAF) is a frequent adverse event after thoracic surgery with associated morbidity, mortality, and healthcare costs. It has been shown to be preventable with prophylactic amiodarone, which is only recommended in high-risk individuals due to the potential associated side effects. Risk factors for POAF have been identified and incorporated into a prediction model to identify high-risk patients. Further evaluation in the form of a multicenter clinical trial is required to assess the effectiveness of prophylaxis specifically in this high-risk population. The feasibility of such a trial first needs to be assessed. METHODS: The PREP-AF trial is a double-blind randomized controlled feasibility trial. Individuals undergoing major thoracic surgery who are identified to be high-risk by the POAF prediction model will be randomized 1:1 to receive a short course of amiodarone vs. placebo in the immediate postoperative period. The primary outcome is feasibility, which will be measured by the number of eligible patients identified, consented, and randomized; intervention adherence; and measurement of future outcomes of a full trial. DISCUSSION: This study will determine the feasibility of a randomized controlled trial to assess the effectiveness of prophylactic amiodarone, in high-risk patients undergoing major thoracic surgery. This will inform the development of a multi-center trial to establish if prophylactic amiodarone is safe and effective at reducing the incidence of POAF. Preventing this adverse event will not only improve outcomes for patients but also reduce the associated health resource utilization and costs. TRIAL REGISTRATION: ClinicalTrials.gov NCT04392921 . Registered on 19 May 2020.
引用
- Smith HA, Kanji S, Tran DTT, et al. Prophylaxis for patients at Risk to Eliminate Post-operative Atrial Fibrillation (PREP-AF trial): a protocol for a feasibility randomized controlled study. Trials. 2021. PMID: 34098992. doi:10.1186/s13063-021-05318-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。